Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
about
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivityAnti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop regionFunctional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.Production and characterization of a soluble, active form of Tva, the subgroup A avian sarcoma and leukosis virus receptorIsolation of virus-neutralizing RNAs from a large pool of random sequences.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Gene therapy for infectious diseasesThree-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomographyEnvelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virusA mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection.MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytesHumoral response to oligomeric human immunodeficiency virus type 1 envelope protein.Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibodyHuman immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposureCD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.Acquisition of CD4-dependence by CD4-independent SIV passaged in human peripheral blood mononuclear cellsNeutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.
P2860
Q24563455-74FB864B-C685-40BE-B151-F611D36B7E3FQ24791794-C0C3A0A3-3CB5-45A3-96B2-3445DD313598Q28343901-E38E6D03-CBBA-42BF-9353-57C96A82A7CBQ28743199-3EE9529B-4C31-483E-BDBB-EC9B8B44B31AQ33426352-5E009926-DFC9-4E92-AFF4-0F8DAF07E3E2Q33504556-86D85B46-2175-4914-8125-3233336C4059Q33559031-61D1C2A9-52ED-4D6A-A224-9DF3207BC684Q33644217-3B491E05-8BC1-4EFD-98AC-6207111FCF6FQ33704732-2451C98B-F8D1-432B-A741-10BB20C3CD8CQ33780620-CE4AABA3-C9B0-4B18-A35A-BC154985DB67Q33810849-C273D05C-3991-4A31-8E33-594B884FAE9EQ33825013-F0BF372A-0AEC-498B-A64E-DBB62B35F2EBQ33851094-DA242C14-15AF-4B69-9F4A-4451DF3F076EQ33961448-263B59ED-E782-443F-B3C1-A528CA67E4BDQ33992464-E29EB8A6-02D7-4847-8B0B-EFF3666D74DFQ34027126-D1BDFD63-0B7A-4D3D-9EEF-80D9DC8EE0D8Q34364045-F978DAA0-3229-4182-B6A4-8D2A8827CCA1Q34434813-45941C50-F441-4AC5-A0E5-2779C5116338Q34572074-BBAE3C44-05C1-4607-871F-03EA49E89A3EQ34681455-131F2E4A-5C60-4277-9B9E-AA7C97D298BEQ35173635-79A6372C-96D8-4B36-AB15-4291C16A7205Q35192782-9747670D-4FAE-4B02-BA23-FD3821969EFEQ35840768-8CE76CA6-BC4C-4BCE-B3B1-FEF83573461FQ35841780-9AD3FB70-39B1-4A89-979A-3903A5576B87Q35848446-10D8A0EF-D7A1-4F9B-BD7D-E1859E4918FAQ35853439-221FF793-961A-4B0C-A426-3BA4C408C9CFQ35854300-0D2ECE95-4D99-4892-99B1-364CBDE0B13BQ35858649-0653A6D8-1792-4238-874E-13BF54FEFBAAQ35859319-4B1CC2D0-16D5-480C-B7CC-CDFC49077BD0Q35866030-47387E12-A339-445F-A60E-6C51D025A5DBQ35868872-061F2109-DE4B-4D15-B82B-83443BF669F2Q35870903-C487694D-AE25-4B27-8E51-FEAAB48B3580Q35876191-B9A74179-A3FF-4626-A956-05E319651A04Q36162633-8B13AA08-4D6D-47C0-88B3-0ED8069CCEC3Q36366296-45A59599-B0AF-4426-BE6E-2802C70AE930Q36484034-8A67C71F-6C48-433C-AF8E-0CD6FDDEA2EFQ36624656-13202D5E-210E-4645-82AB-F650B4B4114FQ36625449-F7D9958D-2E4B-4814-9270-BA3C741BB833Q36627098-CBB82B6D-F213-4E23-A675-DD791766AEE2Q36629914-42FB13FA-8243-4F45-93C2-4B848686D4A0
P2860
Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@ast
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@en
type
label
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@ast
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@en
prefLabel
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@ast
Two mechanisms of soluble CD4 ...... h reduced sensitivity to sCD4.
@en
P2093
P2860
P1433
P1476
Two mechanisms of soluble CD4 ...... th reduced sensitivity to sCD4
@en
P2093
Belperron AA
Kennedy MS
McDougal JS
P2860
P304
P407
P577
1993-03-01T00:00:00Z